Clene goes public with gold-based neurology nanotechnologyBiotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat Share XClene goes public with gold-based neurology nanotechnologyhttps://pharmaphorum.com/news/clene-goes-public-with-gold-based-neurology-nanotechnology/
Lilly to buy private biotech Disarm Therapeutics for up to $1.36bnEli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of Share XLilly to buy private biotech Disarm Therapeutics for up to $1.36bnhttps://pharmaphorum.com/news/lilly-to-buy-private-biotech-disarm-therapeutics-for-up-to-1-36bn/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
Biohaven ALS drug blocked by FDA over manufacturing issueBiohaven’s therapy for amyotrophic lateral sclerosis (ALS) has been rejected by the FDA over manufacturing compliance issues for Share XBiohaven ALS drug blocked by FDA over manufacturing issuehttps://pharmaphorum.com/news/biohaven-als-drug-blocked-by-fda-over-manufacturing-issue/
